- Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
- Legend Biotech to Participate in the Jefferies Global Healthcare Conference
- Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
- Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
- NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
- Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
- Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
- Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
- CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
More ▼
Key statistics
On Friday, Legend Biotech Corp (LEGN:NSQ) closed at 45.57, 18.06% above the 52 week low of 38.60 set on Jun 03, 2024.
52-week range
Open | 45.94 |
---|---|
High | 46.94 |
Low | 45.48 |
Bid | 43.96 |
Offer | 46.00 |
Previous close | 46.56 |
Average volume | 1.77m |
---|---|
Shares outstanding | 182.28m |
Free float | 180.09m |
P/E (TTM) | -- |
Market cap | 7.54bn USD |
EPS (TTM) | -2.60 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼